754 related articles for article (PubMed ID: 32387392)
1. Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections.
Neshani A; Sedighian H; Mirhosseini SA; Ghazvini K; Zare H; Jahangiri A
Microb Pathog; 2020 Sep; 146():104238. PubMed ID: 32387392
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii.
Vila-Farres X; Garcia de la Maria C; López-Rojas R; Pachón J; Giralt E; Vila J
Clin Microbiol Infect; 2012 Apr; 18(4):383-7. PubMed ID: 21672084
[TBL] [Abstract][Full Text] [Related]
3. Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection.
Huang Y; Wiradharma N; Xu K; Ji Z; Bi S; Li L; Yang YY; Fan W
Biomaterials; 2012 Dec; 33(34):8841-7. PubMed ID: 22925814
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
Farzi N; Oloomi M; Bahramali G; Siadat SD; Bouzari S
Probiotics Antimicrob Proteins; 2024 Jun; 16(3):796-814. PubMed ID: 37148452
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of Novel Mastoparan-Chitosan Nanoconstructs Against Clinical MDR
Hassan A; Ikram A; Raza A; Saeed S; Zafar Paracha R; Younas Z; Khadim MT
Int J Nanomedicine; 2021; 16():3755-3773. PubMed ID: 34103914
[TBL] [Abstract][Full Text] [Related]
6. Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii.
Vila-Farrés X; López-Rojas R; Pachón-Ibáñez ME; Teixidó M; Pachón J; Vila J; Giralt E
Eur J Med Chem; 2015 Aug; 101():34-40. PubMed ID: 26114809
[TBL] [Abstract][Full Text] [Related]
7. Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant
Nagarajan D; Roy N; Kulkarni O; Nanajkar N; Datey A; Ravichandran S; Thakur C; T S; Aprameya IV; Sarma SP; Chakravortty D; Chandra N
Sci Adv; 2019 Jul; 5(7):eaax1946. PubMed ID: 31355341
[TBL] [Abstract][Full Text] [Related]
8.
Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
[TBL] [Abstract][Full Text] [Related]
9. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial and Antibiofilm Effects of Peptides from Venom of Social Wasp and Scorpion on Multidrug-Resistant
das Neves RC; Mortari MR; Schwartz EF; Kipnis A; Junqueira-Kipnis AP
Toxins (Basel); 2019 Apr; 11(4):. PubMed ID: 30974767
[TBL] [Abstract][Full Text] [Related]
11. Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse model.
Pan CY; Chen JC; Chen TL; Wu JL; Hui CF; Chen JY
Mar Drugs; 2015 Apr; 13(4):2287-305. PubMed ID: 25874924
[TBL] [Abstract][Full Text] [Related]
12. OmpA Binding Mediates the Effect of Antimicrobial Peptide LL-37 on Acinetobacter baumannii.
Lin MF; Tsai PW; Chen JY; Lin YY; Lan CY
PLoS One; 2015; 10(10):e0141107. PubMed ID: 26484669
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea.
Park YK; Jung SI; Park KH; Kim SH; Ko KS
Int J Antimicrob Agents; 2012 Jan; 39(1):81-5. PubMed ID: 21996405
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.
García-Quintanilla M; Carretero-Ledesma M; Moreno-Martínez P; Martín-Peña R; Pachón J; McConnell MJ
Int J Antimicrob Agents; 2015 Dec; 46(6):696-702. PubMed ID: 26391380
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group.
Conlon JM; Sonnevend A; Pál T; Vila-Farrés X
Int J Antimicrob Agents; 2012 Apr; 39(4):317-20. PubMed ID: 22326566
[TBL] [Abstract][Full Text] [Related]
16. Peptides from American alligator plasma are antimicrobial against multi-drug resistant bacterial pathogens including Acinetobacter baumannii.
Barksdale SM; Hrifko EJ; Chung EM; van Hoek ML
BMC Microbiol; 2016 Aug; 16(1):189. PubMed ID: 27542832
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
[TBL] [Abstract][Full Text] [Related]
18. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.
Rodríguez-Hernández MJ; Saugar J; Docobo-Pérez F; de la Torre BG; Pachón-Ibáñez ME; García-Curiel A; Fernández-Cuenca F; Andreu D; Rivas L; Pachón J
J Antimicrob Chemother; 2006 Jul; 58(1):95-100. PubMed ID: 16636085
[TBL] [Abstract][Full Text] [Related]
19. An engineered arginine-rich α-helical antimicrobial peptide exhibits broad-spectrum bactericidal activity against pathogenic bacteria and reduces bacterial infections in mice.
Yang CH; Chen YC; Peng SY; Tsai AP; Lee TJ; Yen JH; Liou JW
Sci Rep; 2018 Oct; 8(1):14602. PubMed ID: 30279591
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ARV-1502, a Proline-Rich Antimicrobial Peptide, in a Murine Model of Bacteremia Caused by Multi-Drug Resistant (MDR)
Xiong YQ; Li L; Zhou Y; Kraus CN
Molecules; 2019 Aug; 24(15):. PubMed ID: 31382389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
